This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Asselin, B. L. Articles by Cohen, H. J. Search for Related Content PubMed PubMed Citation Articles by Asselin, B. L. Articles by Cohen, H. J.

In Vitro and in Vivo Killing of Acute Lymphoblastic Leukemia Cells by L-Asparaginase¹

Departments of Pediatrics [B. L. A., C. N. F., H. J. C.] and Pathology [D. R.], University of Rochester School of Medicine and Dentistry, Rochester, New York 14642 and Departments of Pediatrics [S. E. S.] and Medicine [S. D. B., P. L.], Dana-Farber Cancer Institute, Boston, Massachusetts 02115

L-Asparaginase (ASNase) is a potent antileukemic enzyme routinely used in the treatment of children with acute lymphoblastic leukemia. As part of investigations of the biological activity of ASNase, we have developed techniques which measure the in vitro and in vivo cell killing ability of ASNase. To study the effect of ASNase on in vitro survival of primary lymphoblasts, bone marrow mononuclear cells obtained from untreated patients with acute lymphoblastic leukemia were cultured with and without ASNase. After 5 days, viable cells were counted using trypan blue exclusion to calculate total cell kill due to ASNase. Propidium iodide exclusion, leukemia cell surface antigens, and flow cytometry were used to determine leukemia cell kill due to ASNase. Comparison of leukemia cell kill and total cell kill showed a direct linear relationship (n = 24, r = 0.7), preferential killing of leukemia cells by ASNase (slope = 0.66), and that use of leukemia cell surface markers yielded a more accurate measurement of leukemia cell killing. ASNase at concentrations from 0.0001 to 0.1 IU/ml had equal effects on extent of leukemia cell killing (P = 0.3 to 0.7), suggesting the absence of a dose response at the ASNase concentrations tested. As a measure of the in vivo response to ASNase treatment, the number of viable bone marrow leukemia cells in the patient prior to and 5 days after treatment with ASNase was measured as the product of (% of rhodamine 123 fluorescent [viable] cells) x (absolute leukemic infiltrate). The change which occurred in the viable leukemic infiltrate was the same for patients whether they received 25,000 or 2,500 IU/m² of ASNase as a single drug. There was a linear correlation (n = 8, r = 0.9) between in vivo and in vitro leukemia cell killing by ASNase. Thus, the in vitro assay described here can be used to predict in vivo sensitivity to ASNase in acute lymphoblastic leukemia.

¹ Supported by Program Project Grant 5P01CA34183-06 from the NIH, FDA Grant 000199-03, USPHS Training Grant HL 07152 (B. L. A.), and Wilmot Cancer Research Fellowship awarded by the James T. Wilmot Foundation (B. L. A.).

² To whom requests for reprints should be addressed, at Department of Pediatrics, Box 777, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642.

Received 12/28/88. Revised 4/27/89. Accepted 5/ 4/89.

This article has been cited by other articles:

				M. Wetzler, B. L. Sanford, J. Kurtzberg, D. DeOliveira, S. R. Frankel, B. L. Powell, J. E. Kolitz, C. D. Bloomfield, and R. A. Larson Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511 Blood, May 15, 2007; 109(10): 4164 - 4167. [Abstract] [Full Text] [PDF]

				M. Duval, S. Suciu, A. Ferster, X. Rialland, B. Nelken, P. Lutz, Y. Benoit, A. Robert, A.-M. Manel, E. Vilmer, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer---Children's Leukemia Group phase 3 trial Blood, April 15, 2002; 99(8): 2734 - 2739. [Abstract] [Full Text] [PDF]

				F. G. Blankenberg, L. Naumovski, J. F. Tait, A. M. Post, and H. W. Strauss Imaging Cyclophosphamide-Induced Intramedullary Apoptosis in Rats Using 99mTc-Radiolabeled Annexin V J. Nucl. Med., February 1, 2001; 42(2): 309 - 316. [Abstract] [Full Text]

				T. C. Abshire, B. H. Pollock, A. L. Billett, P. Bradley, and G. R. Buchanan Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study Blood, September 1, 2000; 96(5): 1709 - 1715. [Abstract] [Full Text] [PDF]

				M. H. Woo, L. J. Hak, M. C. Storm, A. J. Gajjar, J. T. Sandlund, P. L. Harrison, B. Wang, C.-H. Pui, and M. V. Relling Cerebrospinal Fluid Asparagine Concentrations After Escherichia coli Asparaginase in Children With Acute Lymphoblastic Leukemia J. Clin. Oncol., May 1, 1999; 17(5): 1568 - 1568. [Abstract] [Full Text] [PDF]

				F. G. Blankenberg, P. D. Katsikis, J. F. Tait, R. E. Davis, L. Naumovski, K. Ohtsuki, S. Kopiwoda, M. J. Abrams, M. Darkes, R. C. Robbins, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death PNAS, May 26, 1998; 95(11): 6349 - 6354. [Abstract] [Full Text] [PDF]

				G.J.L. Kaspers, A.J.P. Veerman, R. Pieters, C.H. Van Zantwijk, L.A. Smets, E.R. Van Wering, and A. Van Der Does-Van Den Berg In Vitro Cellular Drug Resistance and Prognosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia Blood, October 1, 1997; 90(7): 2723 - 2729. [Abstract] [Full Text] [PDF]

				F. G. Blankenberg, P. D. Katsikis, R. W. Storrs, C. Beaulieu, D. Spielman, J. Y. Chen, L. Naumovski, and J. F. Tait Quantitative Analysis of Apoptotic Cell Death Using Proton Nuclear Magnetic Resonance Spectroscopy Blood, May 15, 1997; 89(10): 3778 - 3786. [Abstract] [Full Text] [PDF]